Form 4: Cidara Therapeutics Acquired by Merck Subsidiary

Cidara Therapeutics director Bonnie L. Bassler reports disposition of shares and options following the company's acquisition by Merck Sharp & Dohme LLC for $221.50 per common share.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its wholly owned subsidiary, Caymus Purchaser, Inc.
• The acquisition was completed on January 7, 2026, following a tender offer.
• Common Shares were acquired for $221.50 per share in cash, without interest and subject to applicable withholding taxes.
• Series A Convertible Voting Preferred Stock was acquired for $15,505.00 per share in cash, without interest and subject to applicable withholding taxes.
• Outstanding stock options became fully vested and were cancelled at the effective time of the merger, converted into the right to receive cash.
• The cash amount for options was calculated as the product of the total number of common shares subject to the option and the excess of the $221.50 merger consideration over the option's exercise price.
• The reporting person, Bonnie L. Bassler, a Director, disposed of 15 Common Shares and various stock options as a result of the merger.
• All reported securities and exercise prices reflect a 1-for-20 reverse stock split effected by Cidara Therapeutics, Inc. on April 24, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a cash premium for their shares and options, indicating a successful exit for the company's public life. However, it marks the end of Cidara as an independent entity, which could be seen as neutral or slightly negative for those who preferred its standalone growth potential.

Positives

• Shareholders received a definitive cash consideration for their shares, providing liquidity and a clear return on investment.
• Holders of in-the-money stock options received cash for their vested options.
• The merger provides a clear exit strategy for Cidara Therapeutics, Inc. as a publicly traded entity.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded company.
• Shareholders no longer participate in the potential future growth or strategic direction of Cidara as a standalone entity.

Future Outlook

Cidara Therapeutics, Inc. will operate as a wholly owned subsidiary of Merck, ceasing to be an independent publicly traded entity. Its future operations and strategic direction will be integrated within Merck's broader corporate strategy.

Industry Context

This acquisition reflects the ongoing consolidation trend in the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to gain access to innovative pipelines, technologies, or market positions. For Merck, the acquisition of Cidara likely strengthens its portfolio in specific therapeutic areas, aligning with its strategic growth objectives.

Comparison to Industry Standards

• The acquisition price of $221.50 per common share and $15,505.00 per Series A share represents the valuation agreed upon by the parties.
• Without specific details on Cidara's pipeline, market capitalization prior to the offer, and comparable transactions, a detailed assessment against industry benchmarks is limited.
• Such transactions typically involve a premium over the pre-announcement trading price, which is standard practice in M&A activities across the pharmaceutical and biotech industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, providing liquidity and a definitive return on investment.
• Employees: Cidara employees are now part of Merck, potentially leading to integration challenges or opportunities within a larger organization.
• Customers/Partners: Business relationships will now be managed under Merck's umbrella.
• Creditors: The company's financial obligations are now backed by Merck.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly owned subsidiary of Merck.
• Integration of Cidara's operations and assets into Merck's corporate structure.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Reverse Stock Split